# Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

> **NCT04807777** · PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 3 (actual)

## Conditions studied

- Advanced Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04807777
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-07
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-10-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Departure of the original investigator
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807777, "Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04807777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*